Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 4Phase 1 4Phase NA 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Glioblastoma 6Gliosarcoma 5Brain Neoplasms 5Prostatic Neoplasms 4Oligodendroglioma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Glioma 3Astrocytoma 3Waldenstrom Macroglobulinemia 2Lymphoma, B-Cell, Marginal Zone 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell 1

Interventions

Docetaxel 33Prednisone 28enzalutamide 19Abiraterone Acetate 13pembrolizumab 11gallium 68 PSMA-11 9Leuprolide 9Radiotherapy 8Pluvicto 8Magnetic Resonance Spectroscopy 8Nivolumab 7Estramustine 7abiraterone 6Radiotherapy, Intensity-Modulated 6Goserelin 6Carboplatin 6Biopsy 6olaparib 5cemiplimab 5bicalutamide 5Specimen Handling 5Paclitaxel 5Cyclophosphamide 5temsirolimus 4orteronel 4darolutamide 4cabazitaxel 4acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4Sirolimus 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Prostatic Neoplasms × temsirolimus × Clear all
NCT01083368 2019-08-21

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

Case Comprehensive Cancer Center

Phase 1/2 Completed
22 enrolled 15 charts
Genitourinary

Prostatic Neoplasms

NCT01026623 2019-06-17

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
16 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

NCT01206036 2016-01-27

CEPTAS

Central European Society for Anticancer Drug Research

Phase 1/2 Completed
19 enrolled
Genitourinary

Prostatic Neoplasms

NCT01020305 2014-10-13

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

Stanford University

Phase 1/2 Terminated
5 enrolled 6 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡